{"title":"Impact of neoadjuvant therapy on angioplastic lobectomy: a retrospective study.","authors":"Tayeb Benkiran, Kheira Hireche, Sebastien Frey, Adeline Morisot, Aude Nguyen, Quentin Rudondy, Florent Alcaraz, Mauro Guarino, Charlotte Cohen, Abel Gomez-Caro, Jean-Phillippe Berthet","doi":"10.1093/icvts/ivae191","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The efficacy of neoadjuvant therapy (NT) prior to angioplastic lobectomy (AL) in non-small cell lung cancer is unclear. This study assessed its impact on morbidity, mortality and 5-year survival.</p><p><strong>Methods: </strong>We retrospectively analysed 114 patients who underwent AL at 2 tertiary centres from January 2000 to December 2020. Comparisons were made between patients who received NT and those who did not.</p><p><strong>Results: </strong>Among the patients, 78 (68.4%) underwent upfront surgery, and 36 (31.6%) received NT. There were no significant differences in postoperative complications (46.2% vs 31.6%, P = 0.42) or mortality rates (0% vs 3.8%, P = 0.55). Pathological upstaging differed significantly (37.2% vs 5.6%, P = 0.0008). Five-year survival rates were comparable (54% vs 38%, P = 0.3).</p><p><strong>Conclusions: </strong>Neoadjuvant therapy does not adversely affect morbidity, arterial repair complications or mortality in AL. There are no survival differences at 5 years. AL remains a safe option following NT.</p>","PeriodicalId":73406,"journal":{"name":"Interdisciplinary cardiovascular and thoracic surgery","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669316/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Interdisciplinary cardiovascular and thoracic surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/icvts/ivae191","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"0","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: The efficacy of neoadjuvant therapy (NT) prior to angioplastic lobectomy (AL) in non-small cell lung cancer is unclear. This study assessed its impact on morbidity, mortality and 5-year survival.
Methods: We retrospectively analysed 114 patients who underwent AL at 2 tertiary centres from January 2000 to December 2020. Comparisons were made between patients who received NT and those who did not.
Results: Among the patients, 78 (68.4%) underwent upfront surgery, and 36 (31.6%) received NT. There were no significant differences in postoperative complications (46.2% vs 31.6%, P = 0.42) or mortality rates (0% vs 3.8%, P = 0.55). Pathological upstaging differed significantly (37.2% vs 5.6%, P = 0.0008). Five-year survival rates were comparable (54% vs 38%, P = 0.3).
Conclusions: Neoadjuvant therapy does not adversely affect morbidity, arterial repair complications or mortality in AL. There are no survival differences at 5 years. AL remains a safe option following NT.
目的：血管成形术肺叶切除术前新辅助治疗对非小细胞肺癌的疗效尚不清楚。本研究评估其对发病率、死亡率和5年生存率的影响。方法：我们回顾性分析了2000年1月至2020年12月在两个三级中心接受血管成形术肺叶切除术的114例患者。对接受新辅助治疗的患者和未接受新辅助治疗的患者进行比较。结果：78例（68.4%）患者接受了前期手术，36例（31.6%）患者接受了新辅助治疗。术后并发症（46.2% vs 31.6%, p = 0.42）和死亡率（0% vs 3.8%, p = 0.55）差异无统计学意义。病理性上位差异有统计学意义（37.2% vs 5.6%, p = 0.0008）。5年生存率具有可比性（54% vs 38%, p = 0.3）。结论：新辅助治疗不会对血管成形术肺叶切除术的发病率、动脉修复并发症或死亡率产生不良影响。5年生存率没有差异。在新辅助治疗后，血管成形术仍是一种安全的选择。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
